[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

January 2020 - April 2015

Decade

Year

Issue

January 2020, Vol 6, No. 1, Pages 3-163

Original Investigation

Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(1):51-59. doi:10.1001/jamaoncol.2019.3702

This phase 2 clinical trial measures the 3-month response rate of selective internal radiotherapy combined with chemotherapy as well as toxic effects, overall and progression-free survival, and disease control rate for patients with unresectable intrahepatic cholangiocarcinoma.

Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(1):60-67. doi:10.1001/jamaoncol.2019.3718

This phase 2 clinical trial evaluates the use of hepatic arterial infusion of floxuridine plus systemic administration of gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma.

Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(1):68-74. doi:10.1001/jamaoncol.2019.3876

This cohort study examines data from the Swedish family-cancer data sets for family history, relative’s age at diagnosis, and other factors to identify the appropriate age for breast cancer screening.

Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(1):75-82. doi:10.1001/jamaoncol.2019.4320

This phase 2 clinical trial of patients with recurrence of breast cancer in the ipsilateral breast assesses the effectiveness of partial breast reirradiation after a second lumpectomy.

Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care

Abstract Full Text
JAMA Oncol. 2020;6(1):84-91. doi:10.1001/jamaoncol.2019.3985

This cohort study develops a machine learning algorithm, using tumors from patients with advanced cancer, to aid in the prediction and classification of tumor types.

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer

Abstract Full Text
JAMA Oncol. 2020;6(1):92-99. doi:10.1001/jamaoncol.2019.3857

This multi-institutional phase 1 clinical trial assesses the safety and tolerability of adding a course of immunotherapy after completion of chemoradiotherapy in patients with node-positive cervical cancer.

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2020;6(1):100-107. doi:10.1001/jamaoncol.2019.3848

This open-label, phase 1/2a study evaluates the safety and activity of fully human glucocorticoid-induced tumor necrosis factor (TNF) receptor–related protein agonist immunoglobulin G1 monoclonal antibody BMS-986156 with or without nivolumab in patients with advanced solid tumors.

Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(1):108-115. doi:10.1001/jamaoncol.2019.4587

This prespecified ancillary study of a randomized clinical trial compares the effects of daily marine ω-3 fatty acid supplementation vs placebo on risk of colorectal cancer precursors, including conventional adenomas and serrated polyps, in an average-risk US population.

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial

Abstract Full Text
open access has active quiz
JAMA Oncol. 2020;6(1):116-124. doi:10.1001/jamaoncol.2019.4782

This randomized clinical trial compared the effect of abemaciclib plus fulvestrant vs placebo plus fulvestrant on overall survival in women with hormone receptor–positive, ERBB2-negative advanced breast cancer that progressed during prior endocrine therapy.

Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(1):125-132. doi:10.1001/jamaoncol.2019.3394

This open-label, single-arm, pilot, phase 1b/2 clinical trial assesses outcomes following treatment with nab-paclitaxel plus gemcitabine plus the platinum-based cisplatin for patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation

Abstract Full Text
online only
JAMA Oncol. 2020;6(1):e192974. doi:10.1001/jamaoncol.2019.2974

This cohort analysis examines the factors associated with successful immune suppression discontinuation in patients who undergo allogeneic hematopoietic cell transplantation and develops a model to estimate the probability of successful discontinuation.

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial

Abstract Full Text
open access online only
JAMA Oncol. 2020;6(1):e193531. doi:10.1001/jamaoncol.2019.3531

This subgroup analysis of a randomized clinical trial compares trifluridine/tipiracil treatment with placebo for progression-free and overall survival among patients with previously treated metastatic gastric or gastroesophageal junction cancer who had or had not undergone gastrectomy.

Research Letter

Racial Disparities in Patient-Reported Measures of Physician Cultural Competency Among Cancer Survivors in the United States

Abstract Full Text
JAMA Oncol. 2020;6(1):152-154. doi:10.1001/jamaoncol.2019.4720

This survey study assesses the role that physician cultural competency plays in racial disparities in cancer incidence and outcomes.

Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017

Abstract Full Text
JAMA Oncol. 2020;6(1):154-156. doi:10.1001/jamaoncol.2019.4906

This cross-sectional study weighs the proportional associations of rising drug costs and use with increased Medicare Part D spending for a cohort of oral anticancer drugs used from 2013 through 2017.

Special Communication

Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer

Abstract Full Text
JAMA Oncol. 2020;6(1):133-141. doi:10.1001/jamaoncol.2019.4117

This Special Communication reports on the discussions and decisions of a multidisciplinary group of experts and patient representatives convened by the US Food and Drug Administration and the National Cancer Institute to examine the state of the science of clinical trials of adjuvant therapies for renal cell carcinoma.

Review

Population-Based Quality Indicators for End-of-Life Cancer Care: A Systematic Review

Abstract Full Text
JAMA Oncol. 2020;6(1):142-150. doi:10.1001/jamaoncol.2019.3388

This systematic review evaluates quality indicators, their measurement properties, and their appropriateness for use in the care of patients with cancer who have advanced disease and/or are at the end of life.

Viewpoint

Neuroendocrine Tumors—Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence

Abstract Full Text
JAMA Oncol. 2020;6(1):21-22. doi:10.1001/jamaoncol.2019.4568

This Viewpoint advocates for additional awareness and allocation of resources to address the increasing incidence of neuroendocrine tumors.

Shots, Not Moonshots—The Importance of Broad Population Immunization to Patients Who Undergo Cancer Treatment

Abstract Full Text
JAMA Oncol. 2020;6(1):23-24. doi:10.1001/jamaoncol.2019.4572

This Viewpoint explores how the association between increased vaccine hesitancy and measles outbreaks affect patients with cancer in the United States.

Progress Toward Precision Medicine in Frontline Treatment of Metastatic Renal Cell Carcinoma

Abstract Full Text
JAMA Oncol. 2020;6(1):25-26. doi:10.1001/jamaoncol.2019.4716

This Viewpoint describes progress toward applying insight into immune checkpoint inhibitor and angiogenesis inhibitor drugs toward cases of metastatic renal cell carcinoma.

Editorial

Moving the Needle Forward With Locoregional Treatment in Unresectable Cholangiocarcinoma—The Jury Is Still Out

Abstract Full Text
JAMA Oncol. 2020;6(1):29-31. doi:10.1001/jamaoncol.2019.3691

Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines

Abstract Full Text
JAMA Oncol. 2020;6(1):31-33. doi:10.1001/jamaoncol.2019.3820

Tumor Origins Through Genomic Profiles

Abstract Full Text
JAMA Oncol. 2020;6(1):33-34. doi:10.1001/jamaoncol.2019.3981
Invited Commentary

Additional Lumpectomy and Irradiation for In-Breast Recurrence of Cancer—When Less Is More

Abstract Full Text
JAMA Oncol. 2020;6(1):82-83. doi:10.1001/jamaoncol.2019.4319
Cancer Care Chronicles

A Daily Struggle to Improve Kaplan-Meier Curves—Doctors on the Swing

Abstract Full Text
JAMA Oncol. 2020;6(1):27-28. doi:10.1001/jamaoncol.2019.3549

In this essay, an oncologist’s describes how he uses the concept of positive deviance and Kaplan-Meier curves in face of treatment obstacles that seem insurmountable.

Poetry and Oncology

A Resident’s Courage

Abstract Full Text
JAMA Oncol. 2020;6(1):163. doi:10.1001/jamaoncol.2019.4741
Comment & Response

Defining Equity in Eligibility for Cancer Screening

Abstract Full Text
JAMA Oncol. 2020;6(1):156. doi:10.1001/jamaoncol.2019.4598

Defining Equity in Eligibility for Cancer Screening—Reply

Abstract Full Text
JAMA Oncol. 2020;6(1):156-157. doi:10.1001/jamaoncol.2019.4604

Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia

Abstract Full Text
JAMA Oncol. 2020;6(1):157-158. doi:10.1001/jamaoncol.2019.4897

Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia

Abstract Full Text
JAMA Oncol. 2020;6(1):158. doi:10.1001/jamaoncol.2019.4900

Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia—Reply

Abstract Full Text
JAMA Oncol. 2020;6(1):158-159. doi:10.1001/jamaoncol.2019.4903

Additional Factors in the Association of Gender and Parenthood With Conference Attendance

Abstract Full Text
JAMA Oncol. 2020;6(1):159. doi:10.1001/jamaoncol.2019.5014

Additional Factors in the Association of Gender and Parenthood With Conference Attendance—Reply

Abstract Full Text
JAMA Oncol. 2020;6(1):160. doi:10.1001/jamaoncol.2019.5022

Going Beyond Results of the PEMBRO-RT Trial

Abstract Full Text
JAMA Oncol. 2020;6(1):160-161. doi:10.1001/jamaoncol.2019.5028

Going Beyond Results of the PEMBRO-RT Trial

Abstract Full Text
JAMA Oncol. 2020;6(1):161-162. doi:10.1001/jamaoncol.2019.5031

Going Beyond Results of the PEMBRO-RT Trial—Reply

Abstract Full Text
JAMA Oncol. 2020;6(1):162. doi:10.1001/jamaoncol.2019.5034
Correction

Error in Author’s Name

Abstract Full Text
free access
JAMA Oncol. 2020;6(1):162. doi:10.1001/jamaoncol.2019.5986

Errors in Results

Abstract Full Text
free access
JAMA Oncol. 2020;6(1):162. doi:10.1001/jamaoncol.2019.6325

Error in Figure

Abstract Full Text
free access
JAMA Oncol. 2020;6(1):162. doi:10.1001/jamaoncol.2019.6336
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2020;6(1):5. doi:10.1001/jamaoncol.2019.4197
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2020;6(1):3. doi:10.1001/jamaoncol.2019.4196
×